RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DI NOIA V
Collezione AOU San Luigi di Orbassano

Items : 5

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.

2021
AOU San Luigi di Orbassano

Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; et alii...

Exploring the role of respiratory microbiome in lung cancer: A systematic review. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Aug;164:103404. doi: 10.1016/j.critrevonc.2021.103404. Epub 2021 Jun 29

2021
ASL Asti
AOU San Luigi di Orbassano

Galetta D; Tiseo M; Menis J; Facchinetti F; Bironzo P; Sartori G; Russano M; Rinaldi S; Prelaj A; Pignataro D; Montrone M; Meacci F; Di Noia V; Bianconi M; Mazzotta M; Perrone F; Belluomini L; Novello S; Pilotto S;

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation. in Journal for immunotherapy of cancer / J Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.

2020
AOU San Luigi di Orbassano

Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.

2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May

2020
AOU San Luigi di Orbassano

Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; et alii...